

**STATUS OF THE CLAIMS**

1-15 (cancelled)

16. (previously presented) A method of protecting ocular neural tissue from damage caused by photodynamic therapy (PDT) treatment comprising delivering a composition to a patient's ocular neural tissue, the composition comprising an amount of brimonidine effective to protect a plurality of ocular neurons from cell death caused by a photoactive component of the PDT treatment as compared to ocular neuron cell death observed in the absence of the administration of said neuroprotectant.

17. (cancelled)

18. (previously presented) The method of claim 16 wherein said brimonidine is administered at a time sufficiently before said PDT treatment to permit localization within ocular tissue prior to said treatment.

19. (previously presented) The method of claim 16 wherein said brimonidine is administered intravenously.

20. (previously presented) The method of claim 16 wherein said brimonidine is administered through intraocular injection.

21. (previously presented) The method of claim 16 wherein said brimonidine is administered by subretinal injection.

22. previously presented) The method of claim 16 wherein said brimonidine is administered by intravitreal injection.

23-29 (cancelled)

30. (currently amended) The method of any of the preceding claims 16 or 18-22 wherein said composition also comprises an therapeutically effective amount of a antiangiogenic compound.

31-38 (cancelled)